What is Leerink Partnrs’ Estimate for TRVI FY2024 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Analysts at Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for shares of Trevi Therapeutics in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($0.49) for the year, down from their previous forecast of ($0.48). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.47) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.47) EPS and FY2026 earnings at ($0.45) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter in the previous year, the business earned ($0.08) earnings per share.

A number of other equities research analysts have also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research note on Tuesday, October 22nd. EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. B. Riley reiterated a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a report on Monday, October 7th. Needham & Company LLC reiterated a “buy” rating and set a $8.00 target price on shares of Trevi Therapeutics in a report on Friday. Finally, Raymond James assumed coverage on Trevi Therapeutics in a research report on Friday, August 30th. They set an “outperform” rating and a $9.00 price target on the stock. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Trevi Therapeutics currently has an average rating of “Buy” and an average target price of $7.43.

Trevi Therapeutics Stock Performance

NASDAQ TRVI opened at $3.07 on Monday. The stock has a fifty day moving average of $3.15 and a 200-day moving average of $2.91. The stock has a market capitalization of $235.98 million, a P/E ratio of -6.77 and a beta of 1.01. Trevi Therapeutics has a 52 week low of $0.97 and a 52 week high of $4.00.

Institutional Investors Weigh In On Trevi Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Logos Global Management LP lifted its stake in Trevi Therapeutics by 27.3% during the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after purchasing an additional 600,000 shares during the last quarter. Opaleye Management Inc. lifted its stake in Trevi Therapeutics by 4.3% during the first quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company’s stock worth $9,125,000 after purchasing an additional 110,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in Trevi Therapeutics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after purchasing an additional 60,249 shares during the last quarter. Ally Bridge Group NY LLC bought a new stake in Trevi Therapeutics during the second quarter worth $4,395,000. Finally, Rosalind Advisors Inc. lifted its stake in Trevi Therapeutics by 50.3% during the second quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock worth $4,147,000 after purchasing an additional 465,561 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Jennifer L. Good sold 10,981 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $644,205.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Jennifer L. Good sold 10,981 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $644,205.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Thomas Sciascia sold 18,660 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the sale, the insider now owns 220,315 shares of the company’s stock, valued at approximately $608,069.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,355 shares of company stock valued at $116,663. 24.37% of the stock is owned by insiders.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.